Qingxin Mu

Acting Assistant Professor

Department of Pharmaceutics, Pharmaceutics Faculty

Telephone: 206-685-3012

Email: qmu@uw.edu

Website: LinkedIn



Accepting Students to Lab: Yes


BE, Pharmaceutical Preparation, Henan University, China

PhD, Medicinal Chemistry, Shandong University, China

Research Interests

  • Drug combination nanoparticle platform (DCNP) for metastatic cancers
  • Advanced and innovative nanoscale drug delivery systems
  • Nanoformulation-biological system interactions

Courses Taught

  • PCEUT505


During the past 15 years, Dr. Mu received multidisciplinary research training from the fields of chemistry, materials science, nanotechnology, cell and molecular biology, immunology, and pharmaceutical sciences. Dr. Mu studied in the Department of Chemical Biology and Therapeutics in St. Jude Children’s Research Hospital as an International Research Scholar from 2007-2009, and then as a postdoc research associate from 2010-2012. From 2012-2017, he furthered his postdoctoral research in Department of Pharmaceutical Chemistry in University of Kansas and Department of Materials Science and Engineering in University of Washington. Since 2017, he joined UW Department of Pharmaceutics as a Research Scientist to study targeted long-acting drug combination nanoparticles (DCNP) for breast cancer treatment (Prof. Rodney Ho laboratory).

Dr. Mu’s primary research goal is to develop advanced and well-understood drug delivery systems for metastatic cancer treatment. His research interests lie in three folds. One is the study of the DCNP approach, for example, the pharmacological understanding and development of a gemcitabine-paclitaxel DCNP injectable for treatment of metastatic breast and pancreatic cancers. The second interest is to design and build innovative drug delivery systems. He has previously investigated various nano-drug carriers based on iron oxide, carbon, polymer and lipids for cancer specific drug delivery and is continuously searching for innovative approaches. He is recently involved in the study of a silicon mesoporous microparticle platform for breast cancer treatment. As in-depth understanding of the drug-nano-bio ternary system helps design successful nanomedicine, the third interest is to study nanoformulation-biological system interactions. For example, mechanisms of nanoparticle cell uptake, in vivo particokinetics, etc.

Selected Publications:


  1. Zhu L, Mu, Q,* Yu J, Griffin JI, Xu X, Ho RJY.* ICAM-1 targeted drug combination nanoparticles enhanced gemcitabine-paclitaxel exposure and breast cancer suppression in mouse models. Pharmaceutics, 2022, 14, 89.
  2. Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY.* Challenges and opportunities in metastatic breast cancer treatments: nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacology & Therapeutics, 2022, 236, 108108.
  3. Mu Q, Lin G, Jeon M, Wang H, Yen T, Revia RA, Halbert M, Zhang M.* Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. Materials Today, Sep 7, 2021. https://doi.org/10.1016/j.mattod.2021.08.002
  4. Yu J,+ Mu Q,+ Perazzolo S, Griffin JI, Zhu L, McConnachie LA, Shen DD, Ho RJY,* Novel long-acting nanoparticles composed of gemcitabine and paclitaxel enhance localization of both drugs in metastatic breast cancer nodules. Pharmaceutical Research. 37(10),197
  5. Mu Q, Lin, G, Stephen ZR, Wang H, Chang F, Patton VK, Gebhart NR, Press OW, Zhang M.* In vivo serum enabled production of ultrafine nanotherapeutics for cancer treatment. Materials Today, 2020, 38, 10-23.
  6. Gao Y,+ Mu Q,+ Zhu L, Li Z, Ho RJY.* Optimizing a novel Au-grafted lipid nanoparticle through chelation chemistry for high photothermal biologic activity, Journal of Pharmaceutical Sciences, 2020, 5(109), 1780-1788.
  7. Mu Q,+ Yu J,+ Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho, RJY.* Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. PLOS ONE, 2020, 15(3):e0228557.
  8. Mu Q,+ Wang H,+* Gu X, Stephen ZR, Yen TY, Chang FC,  Dayringer CJ, Zhang M.* Biconcave Carbon Nanodisk for Enhanced Drug Accumulation and Chemo-photothermal Tumor Therapy. Advanced Healthcare Materials. 2019, 1801505.
  9. Mu Q,* Yan B.* Editorial: Nanoparticles in Cancer Therapy: Novel Concepts, Mechanisms and Applications. Frontiers in Pharmacology, 2019, doi: 10.3389/fphar.2018.01552.
  10. Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho JY.* Translation of Combination Nanodrugs into Nanomedicines: Lessons Learned and Future Outlook, Journal of Drug Targeting, 2018, 26(5-6), 435-447.
  11. Mu Q, Wang H, Zhang M.* (2016) Nanoparticles for Imaging and Treatment of Metastatic Breast Cancer. Expert Opinion on Drug Delivery, 2017, 14(1), 123-136.
  12. Mu Q, Lin G, Patton VK, Wang K, Press OW, Zhang M.* (2016) Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy. Journal of Material Chemistry B, 4(1), 32-36.
  13. Mu Q, Kievit FM, Kant RJ, Lin G, Jeon M, Zhang M.* (2015) Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale, 7(43), 18010-18014.
  14. Mu Q, Jeon M, Hsiao M.-H, Patton VK, Wang K, Press OW, Zhang M.* (2015) Stable and Efficient Paclitaxel Nanoparticles for Targeted Glioblastoma Therapy. Advanced Healthcare Materials, 4(8), 1236-1245.
  15. Hsiao M.-H,+ Mu Q.+, Stephen ZR, Fang C, Zhang M.* (2015) Hexanoyl Chitosan PEG Copolymer Coated Iron Oxide Nanoparticles for Hydrophobic Drug Delivery. ACS Macro Letters, 4(4), 403-407.
  16. Jiao, Q., Li, L.W., Mu, Q.* Zhang, Q.* (2014) Immunomodulation of Nanoparticles in Nanomedicine Applications. BioMed Research International, Volume 2014, Article ID 426028.
  17. Mu, Q., Jiang, G.B., Chen, L.X., Zhou, H.Y., Fourches, D., Tropsha, A., Yan, B.* (2014) Chemical Basis of Interactions between Engineered Nanoparticles and Biological Systems. Chemical Reviews, 114(15), 7740-7781.
  18. Mu, Q., Zhang, Y., Liu, A., Liang, N., Liu, Y., Mu, Y., Su, G., Yan, B.* (2013) Safety of Nanomaterials in Nanomedicinal Applications, Chapter in “Cancer Nanotechnology: Principles and Applications in Radiation Oncology”. 5, 49-61. Taylor & Francis Group.
  19. Mu, Q., Su, G., Li, L., Gilbertson, B.O., Yu, L.H., Zhang, Q., Sun, S.-P., Jiang, G., Yan, B.* (2012) Size-dependent Cellular Uptake of Graphene Oxide Nanosheets. ACS Applied Materials & Interfaces, 4(4), 2259-2266.
  20. Mu, Q., Yang, L., Davis, J.C., Vankayala, R., Hwang, K.C., Zhao, J.C., Yan B.* (2010) Biocompatibility of Polymer Grafted Core/Shell Iron/Carbon Nanoparticles. Biomaterials, 31(19), 5083-5090.
  21. Mu, Q., Zhai, S.M., Yan, B. * (2010) Real-time Monitoring of Cellular Responses to Carbon Nanotubes. Chapter in Methods Mol. Biol. 625, 85-94 — “Carbon Nanotubes: methods and protocols”, Humana Press.
  22. Mu, Q., Broughton, D., Yan B. * (2009) Endosomal Leakage and Nuclear Translocation of Multi-Walled Carbon Nanotubes: Developing a Model for Cell Uptake. Nano Letters, 9(12), 4370-4375.
  23. Mu, Q., Du G.Q., Chen T.S., Zhang B, Yan B.* (2009) Suppression of Human Bone Morphogenetic Protein Signaling by Carboxylated Single-Walled Carbon Nanotubes. ACS Nano, 3(5), 1139-1144.
  24. Mu, Q., Li Z.W., Li X, Mishra S.R., Zhang B, Si Z.K., Yang L, Jiang W, Yan B.* (2009) Characterization of Protein Clusters of Diverse Magnetic Nanoparticles and Their Dynamic Interactions with Human Cells. The Journal of Physical Chemistry C ,113(14), 5390-5395.
  25. Mu, Q., Liu, W., Xing, Y.H., Zhou, H.Y., Li, Z.W., Zhang, Y., Ji, L.H., Wang, F., Si, Z.K., Zhang, B., Yan, B.* (2008) Protein Binding by Functionalized Multiwalled Carbon Nanotubes Is Governed by the Surface Chemistry of Both Parties and the Nanotube Diameter. The Journal of Physical Chemistry C, 112(9), 3300-3307.